Skip to main content

Advertisement

Log in

Chronic kidney disease perspectives in Japan and the importance of urinalysis screening

  • Review Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

There are racial differences in primary renal diseases for end-stage renal disease (ESRD) and the incidence and prevalence of cardiovascular disease (CVD). To reduce the number of patients with both ESRD and CVD, an effective screening method for CKD should be established. In Japan, screening with the urine dip-stick test for proteinuria has been used since 1972 targeting every child and worker and since 1983 for every resident over 40 years old. There are several reasons for continuing this screening program. First, the positive rate of proteinuria is high in the Japanese general population, especially subjects with neither hypertension nor diabetes. Most of these subjects have no symptoms, and the only sign of renal disease is asymptomatic urinary abnormalities. Second, the prevalence and incidence of glomerulonephritis, especially IgA nephropathy, are high in the Japanese and Asian races, and urinalysis is the only method for early detection of chronic glomerulonephritis. Third, 10-year survival of the ESRD patients due to glomerulonephritis was approximately twice that of ESRD patients due to diabetes and nephrosclerosis. Consequently, reducing the incidence of ESRD due to glomerulonephritis is one of the best ways to reduce the prevalence of ESRD. Furthermore, higher incidence of ESRD in Asian races than in Caucasians was reported. Proteinuria is known to be the best predictor for reducing renal function, and the urine dip-stick test for proteinuria is less expensive and is cost-effective. For an effective screening strategy to reduce the ESRD population in Japanese and Asians, universal screening with the urine dip-stick test for proteinuria could be one solution.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol. 2001;12:2753–8.

    CAS  PubMed  Google Scholar 

  2. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol. 2002;13(Suppl 1):S37–40.

    PubMed  Google Scholar 

  3. Nakai S, Masagane I, Akiba T, Iseki K, Watanabe Y, Itami Y, et al. An overview of dialysis treatment in Japan (as of Dec. 31, 2005). J Jpn Soc Dial Ther. 2007;40:1–30.

    Article  Google Scholar 

  4. Systems USRD: USRDS 2006 Annual Data Report. Bethesda: National Institute of Health; 2007.

  5. Fukuhara S, Lopes AA, Bragg-Gresham JL, Kurokawa K, Mapes DL, Akizawa T, et al. Health-related quality of life among dialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2003;64:1903–10.

    Article  PubMed  Google Scholar 

  6. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease. Am J Kidney Dis. 2002;39:76–110.

    Article  Google Scholar 

  7. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–100.

    Article  PubMed  Google Scholar 

  8. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12.

    Article  PubMed  Google Scholar 

  9. Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int. 2005;67(Suppl 98):S7–10.

    Article  Google Scholar 

  10. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32:853–906.

    Article  CAS  PubMed  Google Scholar 

  11. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285–95.

    Article  CAS  PubMed  Google Scholar 

  12. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307–15.

    Article  PubMed  Google Scholar 

  13. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.

    Article  CAS  PubMed  Google Scholar 

  14. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489–95.

    Article  PubMed  Google Scholar 

  15. Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, et al. The burden of kidney disease: improving global outcomes. Kidney Int. 2004;66:1310–4.

    Article  PubMed  Google Scholar 

  16. Uhlig K, Macleod A, Craig J, Lau J, Levey AS, Levin A, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;70:2058–65.

    Article  CAS  PubMed  Google Scholar 

  17. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis. 2000;35:157–65.

    Article  CAS  PubMed  Google Scholar 

  18. Racial differences in trends of end-stage renal disease, by primary diagnosis-United States, 1994–2004. MMWR Morb Mortal Wkly Rep. 2007;56:253–6.

  19. Hemmelgarn BR, Chou S, Wiebe N, Culleton BF, Manns BJ, Klarenbach S, et al. Differences in use of peritoneal dialysis and survival among East Asian, Indo Asian, and white ESRD patients in Canada. Am J Kidney Dis. 2006;48:964–71.

    Article  PubMed  Google Scholar 

  20. Yamagata K, Takahashi H, Suzuki S, Mase K, Hagiwara M, Shimizu Y, et al. Age distribution and yearly changes in the incidence of end-stage renal disease in Japan. Am J Kidney Dis. 2004;43:433–43.

    Article  PubMed  Google Scholar 

  21. World Health Organization: World Health Statistics 2006, 2007.

  22. Wu Z, Yao C, Zhao D, Wu G, Wang W, Liu J, et al. Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in China, Part I: morbidity and mortality monitoring. Circulation. 2001;103:462–8.

    Article  CAS  PubMed  Google Scholar 

  23. Yamagata K, Takahashi H, Tomida C, Yamagata Y, Koyama A. Prognosis of asymptomatic hematuria and/or proteinuria in men. Nephron. 2002;91:34–42.

    Article  PubMed  Google Scholar 

  24. Ishida K, Ishida H, Narita M, Sairenchi T, Saito Y, Fukutomi H, et al. Factors affecting renal function in 119 985 adults over three years. QJM. 2001;94:541–50.

    Article  CAS  PubMed  Google Scholar 

  25. Woolhandler S, Pels RJ, Bor DH, Himmelstein DU, Lawrence RS. Dipstick urinalysis screening of asymptomatic adults for urinary tract disorders. I. Hematuria and proteinuria. JAMA. 1989;262:1214–9.

    Article  CAS  PubMed  Google Scholar 

  26. Nephrology TSo: Anual data report of ESRD in Taiwan. https://doi.org/www.tsn.org.tw/ (2006).

  27. Caskey FJ, Schober-Halstenberg HJ, Roderick PJ, Edenharter G, Ansell D, Frei U, et al. Exploring the differences in epidemiology of treated ESRD between Germany and England and Wales. Am J Kidney Dis. 2006;47:445–54.

    Article  PubMed  Google Scholar 

  28. Registry AaNZDaT: The 29th Annual Report 2006 Report—Data to 2005. https://doi.org/www.anzdata.org.au/ (2007).

  29. Stewart JH, McCredie M, Disney AP, Mathew TH. Trends in incidence of end-stage renal failure in Australia, 1972–1991. Nephrol Dial Transplant. 1994;9:1377–82.

    CAS  PubMed  Google Scholar 

  30. Wimmer F, Oberaigner W, Kramar R, Mayer G. Regional variability in the incidence of end-stage renal disease: an epidemiological approach. Nephrol Dial Transplant. 2003;18:1562–7.

    Article  PubMed  Google Scholar 

  31. Kuo HW, Tsai SS, Tiao MM, Yang CY. Epidemiological features of CKD in Taiwan. Am J Kidney Dis. 2007;49:46–55.

    Article  PubMed  Google Scholar 

  32. Tiebosch ATMG, Wolters J, Frederik PFM, van der Wiel TWM, Zeppenfeldt E, van Breda Vriesman PJC. Epidemiology of idiopathic glomerular disease: a prospective study. Kidney Int. 1987;32:112–6.

    Article  CAS  PubMed  Google Scholar 

  33. Simon P, Ramee MP, Autuly V, Laruelle E, Charasse C, Cam G, et al. Epidemiology of primary glomerular diseases in a Frecnch region. Variations according to period of age. Kidney Int. 1994;46:1192–8.

    Article  CAS  PubMed  Google Scholar 

  34. Koyama A, Igarashi M, Kobayashi M. Naturals history and risk factors for immunoglobulin A nephropathy. Am J Kid Dis. 1997;29:526–32.

    Article  CAS  PubMed  Google Scholar 

  35. Cameron JS. Proteinuria and progression in human glomerular diseases. Am J Nephrol. 1990;1:81–7.

    Article  Google Scholar 

  36. Cameron JS. The long-term outcome of glomerular diseases. 6th ed. Boston/Tronto/London: Little Brown and Company;1997.

    Google Scholar 

  37. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468–74.

    Article  PubMed  Google Scholar 

  38. Usui J, Yamagata K, Kai H, Outeki T, Yamamoto S, Muro K, et al. Heterogeneity of prognosis in adult IgA nephropathy, especially with mild proteinuria or mild histological features. Intern Med. 2001;40:697–702.

    Article  CAS  PubMed  Google Scholar 

  39. Keane WF. Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis. 2000;35:S97–105.

    Article  CAS  PubMed  Google Scholar 

  40. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest. 2006;116:288–96.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  41. Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis. 2001;38:728–35.

    Article  CAS  PubMed  Google Scholar 

  42. Nagai R, Wang EEL, Feldman W. Dipstick proteinuria screening of asymptomatic adults to prevent progressive renal disease. In: Canadian Task Force on the Periodic Health Examination. Otawa: Health Canada; 1994.

  43. Murakami M, Hayakawa M, Yanagihara T, Hukunaga Y. Proteinuria screening for children. Kidney Int Suppl. 2005; 67:S23–7.

    Article  Google Scholar 

  44. D’Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Quart J Med. 1987;64:709–27.

    PubMed  Google Scholar 

  45. Nair R, Walker PD. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int. 2006;69:1455–8.

    Article  CAS  PubMed  Google Scholar 

  46. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139:244–52.

    Article  CAS  PubMed  Google Scholar 

  47. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int. 2002;62:1020–5.

    Article  CAS  PubMed  Google Scholar 

  48. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353:883–7.

    Article  CAS  PubMed  Google Scholar 

  49. Shoji T, Nakanishi I, Suzuki A, Hayashi T, Togawa M, Okada N, et al. Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis. 2000;35:194–201.

    Article  CAS  PubMed  Google Scholar 

  50. Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.

    Article  CAS  PubMed  Google Scholar 

  51. Xie Y, Nishi S, Ueno M, Imai N, Sakatsume M, Narita I, et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int. 2003;63:1861–7.

    Article  PubMed  Google Scholar 

  52. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003;290:3101–14.

    Article  CAS  PubMed  Google Scholar 

  53. Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int. 2002;61:2165–75.

    Article  PubMed  Google Scholar 

  54. Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71:159–66.

    Article  CAS  PubMed  Google Scholar 

  55. Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int. 1996;49:800–5.

    Article  CAS  PubMed  Google Scholar 

  56. Yamagata K, Yamagata Y, Kobayashi M, Koyama A. A long-term follow-up study of asymptomatic hematuria and/or proteinuria in adults. Clin Nephrol. 1996;45:281–8.

    CAS  PubMed  Google Scholar 

  57. Ramirez SP, McClellan W, Port FK, Hsu SI. Risk factors for proteinuria in a large, multiracial, southeast Asian population. J Am Soc Nephrol. 2002;13:1907–17.

    Article  PubMed  Google Scholar 

  58. Halbesma N, Kuiken DS, Brantsma AH, Bakker SJ, Wetzels JF, De Zeeuw D, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol. 2006;17:2582–90.

    Article  PubMed  Google Scholar 

  59. Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ. 2006;333:1047.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Chandie Shaw PK, Baboe F, van Es LA, van der Vijver JC, van de Ree MA, de Jonge N, et al. South-Asian type 2 diabetic patients have higher incidence and faster progression of renal disease compared with Dutch–European diabetic patients. Diabetes Care. 2006;29:1383–5.

    Article  PubMed  Google Scholar 

  61. Burden AC, McNally PG, Feehally J, Walls J. Increased incidence of end-stage renal failure secondary to diabetes mellitus in Asian ethnic groups in the United Kingdom. Diabet Med. 1992;9:641–5.

    Article  CAS  PubMed  Google Scholar 

  62. Lightstone L, Rees AJ, Tomson C, Walls J, Winearls CG, Feehally J. High incidence of end-stage renal disease in Indo-Asians in the UK. QJM. 1995;88:191–5.

    CAS  PubMed  Google Scholar 

  63. Iyengar SK, Abboud HE, Goddard KA, Saad MF, Adler SG, Arar NH, et al. Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: the family investigation of nephropathy and diabetes (FIND). Diabetes. 2007;56:1577–85.

    Article  CAS  PubMed  Google Scholar 

  64. Trehan A, Winterbottom J, Lane B, Foley R, Venning M, Coward R, et al. End-stage renal disease in Indo-Asians in the North-West of England. QJM. 2003;96:499–504.

    Article  CAS  PubMed  Google Scholar 

  65. Brown WW, Peters RM, Ohmit SE, Keane WF, Collins A, Chen SC, et al. Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2003;42:22–35.

    Article  PubMed  Google Scholar 

  66. McGill JB, Brown WW, Chen SC, Collins AJ, Gannon MR. Kidney Early Evaluation Program (KEEP). Findings from a community screening program. Diabetes Educ. 2004;30:196–8 (200–192, 206).

    Article  PubMed  Google Scholar 

  67. Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006;17:2275–84.

    Article  PubMed  Google Scholar 

  68. Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006;69:1264–71.

    Article  CAS  PubMed  Google Scholar 

  69. Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005;68:228–36.

    Article  PubMed  Google Scholar 

  70. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777–82.

    Article  CAS  PubMed  Google Scholar 

  71. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, et al. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol. 2004;33:189–98.

    Article  PubMed  Google Scholar 

  72. Dell’Omo G, Penno G, Giorgi D, Di Bello V, Mariani M, Pedrinelli R. Association between high-normal albuminuria and risk factors for cardiovascular and renal disease in essential hypertensive men. Am J Kidney Dis. 2002;40:1–8.

    Article  PubMed  Google Scholar 

  73. Remuzzi G, Weening JJ. Albuminuria as early test for vascular disease. Lancet. 2005;365:556–7.

    Article  PubMed  Google Scholar 

  74. de Jong PE, Brenner BM. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int. 2004;66:2109–18.

    Article  PubMed  Google Scholar 

  75. Konta T, Hao Z, Abiko H, Ishikawa M, Takahashi T, Ikeda A, et al. Prevalence and risk factor analysis of microalbuminuria in Japanese general population: the Takahata study. Kidney Int. 2006;70:751–6.

    Article  CAS  PubMed  Google Scholar 

  76. Jafar TH, Chaturvedi N, Hatcher J, Levey AS. Use of albumin creatinine ratio and urine albumin concentration as a screening test for albuminuria in an Indo-Asian population. Nephrol Dial Transplant. 2007.

  77. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110:921–7.

    Article  CAS  PubMed  Google Scholar 

  78. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309–20.

    Article  PubMed  Google Scholar 

  79. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the reduction of endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial. J Am Soc Nephrol. 2007;18:1540–6.

    Article  CAS  PubMed  Google Scholar 

  80. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.

    Article  CAS  PubMed  Google Scholar 

  81. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001;60:1131–40.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kunihiro Yamagata.

About this article

Cite this article

Yamagata, K., Iseki, K., Nitta, K. et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol 12, 1–8 (2008). https://doi.org/10.1007/s10157-007-0010-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-007-0010-9

Keywords

Navigation